Benzinga -
- Monopar Therapeutics Inc (NASDAQ: MNPR) released data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft tissue sarcoma patients.
- The prior exploratory clinical studies of camsirubicin in cancer patients showed the potential to treat patients with high doses for a year or longer.
- The preclinical and exploratory clinical studies showed no irreversible heart toxicity with camsirubicin, as seen in doxorubicin, one of the most widely used cancer drugs worldwide.
- The Phase 1b clinical trial has enrolled 11 patients. 5 of 10 patients have exhibited stable disease at 12 weeks. 1 patient met the criteria for SD at the first CT scan (6 weeks) but unfortunately died due to COVID-19 and was not evaluable at the 12-week CT scan.
- The ASTS subtype patients achieving stable disease on camsirubicin are in line with those more likely to respond to doxorubicin.
- The trial is presently at the fourth dose-level cohort (520mg/m2), almost twice the trial's starting dose.
- No drug-related clinical cardiotoxicity has been observed in any patient. The trial continues to enroll and dose-escalate, as there have been no signs of hitting the maximum tolerated dose.
- Price Action: MNPR shares are up 0.36% at $2.82 on the last check Wednesday.